DC Chemicals · Product datasheet
9-ING-41 · DC11827
9-ING-41 (Elraglusib) is a cancer-research compound originally developed as a GSK-3β inhibitor. Published work documents model-dependent growth inhibition and additional mechanisms.
| Parameter | Value |
|---|---|
| Chemical Name | 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione |
| CAS No. | 1034895-42-5 |
| Synonyms | 9ING41; 9-ING 41 |
| Formula | C22H13FN2O5 |
| M.Wt | 404.34 |
| SMILES | N1C(=O)C(C2=COC3C2=CC(=CC=3)F)=C(C2=CN(C)C3C=C4C(=CC2=3)OCO4)C1=O |
| Purity | On request |
| Storage | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Biological activity summary
9-ING-41 (Elraglusib) is a cancer-research compound originally developed as a GSK-3β inhibitor. Published work documents model-dependent growth inhibition and additional mechanisms.
View referenced In Vitro and In Vivo results on the product pageReferences
- Poloznikov A, et al. 9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells. Frontiers in pharmacology (2021).
- Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition. Cell communication and signaling : CCS (2023).
Available packs
- 100 mg · US$600
- 250 mg · US$1,100
- 1 g · US$2,200
- 10 mM * 1 mL in DMSO · US$220